Chemed (CHE) Scheduled to Post Quarterly Earnings on Tuesday

Chemed (NYSE:CHEGet Rating) is set to issue its quarterly earnings data after the market closes on Tuesday, April 26th. Analysts expect the company to announce earnings of $4.49 per share for the quarter. Chemed has set its FY 2022 guidance at $19.100-$19.500 EPS and its FY22 guidance at $19.10-$19.50 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Chemed (NYSE:CHEGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported $5.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.06 by $0.19. The company had revenue of $541.00 million during the quarter, compared to the consensus estimate of $543.18 million. Chemed had a net margin of 12.55% and a return on equity of 38.47%. The firm’s revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.13 EPS. On average, analysts expect Chemed to post $19 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Chemed stock opened at $490.77 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 0.76 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $7.35 billion, a PE ratio of 29.07, a P/E/G ratio of 3.11 and a beta of 0.53. The firm has a fifty day simple moving average of $485.28 and a two-hundred day simple moving average of $483.00. Chemed has a twelve month low of $403.00 and a twelve month high of $539.87.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 18th. Shareholders of record on Monday, February 28th were paid a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend was Friday, February 25th. Chemed’s dividend payout ratio is presently 8.53%.

A number of research firms have issued reports on CHE. StockNews.com began coverage on shares of Chemed in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $496.00 price objective on the stock in a research report on Friday, January 21st. Finally, Royal Bank of Canada decreased their price objective on shares of Chemed from $609.00 to $579.00 and set an “outperform” rating on the stock in a research report on Friday, March 4th.

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction dated Tuesday, March 8th. The shares were sold at an average price of $469.91, for a total transaction of $1,409,730.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Spencer S. Lee sold 1,054 shares of the business’s stock in a transaction dated Monday, March 7th. The shares were sold at an average price of $487.39, for a total transaction of $513,709.06. The disclosure for this sale can be found here. Insiders sold 4,459 shares of company stock worth $2,134,537 in the last 90 days. Corporate insiders own 3.69% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC purchased a new stake in Chemed in the fourth quarter worth about $229,000. Cubist Systematic Strategies LLC grew its holdings in Chemed by 80.8% in the fourth quarter. Cubist Systematic Strategies LLC now owns 940 shares of the company’s stock worth $497,000 after purchasing an additional 420 shares during the period. Metropolitan Life Insurance Co NY grew its holdings in Chemed by 3.6% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 2,933 shares of the company’s stock worth $1,552,000 after purchasing an additional 101 shares during the period. LPL Financial LLC grew its holdings in Chemed by 4.0% in the fourth quarter. LPL Financial LLC now owns 2,969 shares of the company’s stock worth $1,571,000 after purchasing an additional 113 shares during the period. Finally, Allianz Asset Management GmbH grew its holdings in Chemed by 73.2% in the fourth quarter. Allianz Asset Management GmbH now owns 7,702 shares of the company’s stock worth $4,075,000 after purchasing an additional 3,256 shares during the period. Institutional investors own 88.38% of the company’s stock.

Chemed Company Profile (Get Rating)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Articles

Earnings History for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.